Raras
Buscar doenças, sintomas, genes...
Histidinemia
ORPHA:2157CID-10 · E70.8CID-11 · 5C50.20OMIM 235800DOENÇA RARA

A histidinemia é um distúrbio metabólico raro caracterizado por níveis elevados de histidina no sangue, na urina e no líquido cefalorraquidiano, geralmente sem repercussões clínicas.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A histidinemia é um distúrbio metabólico raro caracterizado por níveis elevados de histidina no sangue, na urina e no líquido cefalorraquidiano, geralmente sem repercussões clínicas.

Publicações científicas
142 artigos
Último publicado: 2025 Nov 28

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
Infancy
+ neonatal
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: E70.8
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (6)
0202010279
Dosagem de aminoácidos (erros inatos)metabolic_test
0202010295
Dosagem de ácidos orgânicos na urinagenetic_test
0202010490
Teste de triagem para erros inatos do metabolismonewborn_screening
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202080013
Teste do pezinho (triagem neonatal)
0301070040
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
5 sintomas
🦴
Ossos e articulações
5 sintomas
😀
Face
3 sintomas
👂
Ouvidos
2 sintomas
📏
Crescimento
2 sintomas
❤️
Coração
1 sintomas

+ 7 sintomas em outras categorias

Características mais comuns

100%prev.
Hiperhistidinemia
Frequência: 50/50
100%prev.
Histidinúria
3%prev.
Atraso global do desenvolvimento moderado
Raro (<5%)
3%prev.
Comportamento atípico
Raro (<5%)
3%prev.
Anormalidade da fala ou vocalização
Raro (<5%)
3%prev.
Hiperatividade
Raro (<5%)
26sintomas
Muito frequente (2)
Muito raro (6)
Sem dados (18)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 26 características clínicas mais associadas, ordenadas por frequência.

HiperhistidinemiaHyperhistidinemia
Frequência: 50/50100%
HistidinúriaHistidinuria
Muito frequente100%
Atraso global do desenvolvimento moderadoModerate global developmental delay
Raro (<5%)3%
Comportamento atípicoAtypical behavior
Raro (<5%)3%
Anormalidade da fala ou vocalizaçãoAbnormality of speech or vocalization
Raro (<5%)3%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico142PubMed
Últimos 10 anos7publicações
Pico20242 papers
Linha do tempo
2025Hoje · 2026
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal recessive.

HALHistidine ammonia-lyaseDisease-causing germline mutation(s) inTolerante
LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Histidine catabolism
MECANISMO DE DOENÇA

Histidinemia

Autosomal recessive disease characterized by increased histidine and histamine as well as decreased urocanic acid in body fluids.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
86.9 TPM
Skin Sun Exposed Lower leg
39.0 TPM
Skin Not Sun Exposed Suprapubic
31.9 TPM
Sangue
23.8 TPM
Baço
7.9 TPM
OUTRAS DOENÇAS (1)
histidinemia
HGNC:4806UniProt:P42357

Variantes genéticas (ClinVar)

7 variantes patogênicas registradas no ClinVar.

🧬 HAL: NM_002108.4(HAL):c.1762del (p.Arg588fs) ()
🧬 HAL: NM_002108.4(HAL):c.1520-5_1538del ()
🧬 HAL: GRCh37/hg19 12p13.33-q24.33(chr12:173787-133777902) ()
🧬 HAL: GRCh37/hg19 12p13.33-q24.33(chr12:173787-133777902)x3 ()
🧬 HAL: GRCh37/hg19 12p13.33-q24.33(chr12:1-133851895)x3 ()
Ver todas no ClinVar

Vias biológicas (Reactome)

1 via biológica associada aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Histidinemia

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
7 papers (10 anos)
#1

Histidine ammonia lyase expression characteristics in primary liver cancer: hepatocellular carcinoma and cholangiocarcinoma.

Discover oncology2025 Nov 28

Histidine (His) ammonia Lyase (HAL) is a key rate-limiting enzyme that catalyzes the first reaction in the metabolism of histidine. Deficiencies in HAL lead to histidinemia, characterized by elevated levels of His in the blood and other body fluids. The level of HAL in these fluids is known to impact the sensitivity of cancer cells to certain chemotherapeutics by regulating His. However, the molecular role and impacts of HAL in the progression of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are unknown at present. Thus, we investigated the expression of HAL in HCC and CCA tumors. The Cancer Genome Atlas (TCGA) database, quantitative real-time PCR (qRT-PCR), and immunoblot analysis were utilized to examine the expression of HAL in HCC and CCA patients. TCGA analysis revealed a significant downregulation of HAL mRNA expression in HCC and CCA tumor tissues compared with normal tissues (p < 0.0001). Our qRT-PCR and immunoblot analysis demonstrated a significant decrease in both HAL mRNA (HCC, n = 9, p < 0.05; CCA, n = 7, p < 0.05) and protein levels (HCC, 91.7%, 22/24; CCA, 92.9%, 13/14) in both HCC and CCA tumor tissues compared with adjacent non-tumor liver/ bile duct tissues across the majority of patient samples analyzed. The protein expression pattern aligns with the mRNA findings, indicating that HAL downregulation occurs at both transcriptional and protein levels. Our data evinced the relevance and significance of HAL in the tumorigenesis of HCC and CCA. These findings suggest that HAL and its metabolic derivatives can be developed as a potential prognostic and diagnostic biomarker as well as therapeutics for HCC and CCA.

#2

Pleiotropic Nanostructures Built from l-Histidine Show Biologically Relevant Multicatalytic Activities.

ACS applied materials &amp; interfaces2024 Apr 17

The essential amino acid histidine plays a central role in the manifestation of several metabolic processes, including protein synthesis, enzyme-catalysis, and key biomolecular interactions. However, excess accumulation of histidine causes histidinemia, which shows brain-related medical complications, and the molecular mechanism of such histidine-linked complications is largely unknown. Here, we show that histidine undergoes a self-assembly process, leading to the formation of amyloid-like cytotoxic and catalytically active nanofibers. The kinetics of histidine self-assembly was favored in the presence of Mg(II) and Co(II) ions. Molecular dynamics data showed that preferential noncovalent interactions dominated by H-bonds between histidine molecules facilitate the formation of histidine nanofibers. The histidine nanofibers induced amyloid cross-seeding reactions in several proteins and peptides including pathogenic Aβ1-42 and brain extract components. Further, the histidine nanofibers exhibited oxidase activity and enhanced the oxidation of neurotransmitters. Cell-based studies confirmed the cellular internalization of histidine nanofibers in SH-SY5Y cells and subsequent cytotoxic effects through necrosis and apoptosis-mediated cell death. Since several complications including behavioral abnormality, developmental delay, and neurological disabilities are directly linked to abnormal accumulation of histidine, our findings provide a foundational understanding of the mechanism of histidine-related complications. Further, the ability of histidine nanofibers to catalyze amyloid seeding and oxidation reactions is equally important for both biological and materials science research.

#3

Dual-emissive europium doped UiO-66-based ratiometric light-up biosensor for highly sensitive detection of histidinemia biomarker.

Analytica chimica acta2024 Feb 15

Lanthanide metal-organic frameworks (Ln-MOFs) are a kind of emerging crystalline porous materials with high fluorescence and easy-to-tunable properties, making them ideal for sensing applications. However, current Ln-MOFs based fluorescent probes are primarily single-emissive or fluorescence-quenched, which greatly limited the detection performances such as sensitivity, accuracy and repeatability, thereby hindering their applications in efficient target monitoring and related disease diagnosis. To address these issues, the reasonable design of Ln-MOFs equipped with dual fluorescence emissions and light-up mode is urgently needed for a high-performance biosensor. A dual-emissive europium doped UiO-66 (Eu@UiO-66-NH2-PMA)-based ratiometric fluorescent biosensing platform was constructed for highly sensitive and selective detection of the histidinemia biomarker-histidine (His). Eu@UiO-66-NH2-PMA (pyromellitic acid abbreviated as PMA) was synthesized utilizing a post-synthetic modification method via coordination interactions between the free -COOH of UiO-66-NH2-PMA and Eu3+, which exhibited characteristic peaks of broad ligand emission and sharp Eu3+ emissions simultaneously. Considering that Cu2+ had the excellent fluorescence quenching ability toward Eu3+ and superior affinity with His, it was deliberately introduced into the Eu@UiO-66-NH2-PMA, acting as active sites for target His responsiveness. The Eu@UiO-66-NH2-PMA/Cu2+/His ternary competition system demonstrated a low detection limit of 74 nM, excellent selectivity and good anti-interference capability that allowed for sensitive analysis of His levels in milk and human serum samples. Attributing to the superior luminescent properties, good stability and self-calibration capability of Eu@UiO-66-NH2-PMA, the developed ratiometric light-up sensing platform enabled sensitive, selective and credible analysis of His in complex practical samples, which might provide an available tool for food nutrition guideline and diagnostic applications of His related diseases.

#4

The self-assembly of L-histidine might be the cause of histidinemia.

Scientific reports2023 Oct 14

L-Histidine is an essential amino acid with unique biochemical and physiological properties. Histidinemia is a disease condition caused by the elevated level of L-histidine in our blood. Mutations in the histidase, an enzyme for the breakdown of histidine, is the cause of the rise in histidine concentration. To our knowledge, no research has been done on why a high concentration of histidine causes histidinemia. In this study, we provide a potential explanation why the elevated levels of histidine in the human body causes histidinemia. In this study we have found that L-histidine self-assembled in water to form nano sheet structures at physiological pH and temperature, using 1D 1H NMR spectroscopy, diffusion ordered spectroscopy (DOSY) and scanning electron microscope (SEM) techniques. The kinetics of self-assembly has been studied using real time NMR spectroscopy. We observed that both the aromatic ring and aliphatic part are equally contributing to the self-assembly of L-histidine. The symptoms of histidinemia, neurological deficits and speech delays, are similar to that of the neurodegenerative diseases caused by the self-assembly of peptides and proteins. We speculate that the self-assembly of L-histidine might be the cause of histidinemia.

#5

Spiropyran-modified upconversion nanocomposite as a fluorescent sensor for diagnosis of histidinemia.

RSC advances2020 Jul 15

Histidinemia is a congenital metabolic disorder where the histidine (His) metabolism is blocked, resulting in increased concentrations of His in blood and urine. The disease causes an abnormal development of the patient's nervous system, which leads to many serious illnesses. Therefore, it is very important to diagnose early. In this study, we developed a novel fluorescent nanosensor NaGdF4:Yb3+, Er3+@SiO2-spiropyran (UCNP@SiO2-SP). The nanosensor displayed a "turn-off" fluorescence response towards His. When His was mixed with UCNP@SiO2-SP, His could specifically bind to SP, which could cause the isomerization of SP. The structure of SP was changed from spiroform into merocyanine form. The luminescence of the sensor was overlapped with the absorption of the merocyanine form. As a result, His will lead to fluorescence quenching of the sensor based on inner filter effects (IFE), which can be used to detect His. Importantly, as the first report of a UCNP@SiO2-SP nanosensor for detecting His, this method exhibits good selectivity and anti-interference capability. The detection limit is 4.4 μM. In addition, the amount of His in urine was also measured, suggesting the applicability of this sensor for histidinemia diagnosis.

Publicações recentes

Ver todas no PubMed

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Histidinemia.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Histidinemia

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Histidine ammonia lyase expression characteristics in primary liver cancer: hepatocellular carcinoma and cholangiocarcinoma.
    Discover oncology· 2025· PMID 41313389mais citado
  2. Pleiotropic Nanostructures Built from l-Histidine Show Biologically Relevant Multicatalytic Activities.
    ACS applied materials &amp; interfaces· 2024· PMID 38564419mais citado
  3. Dual-emissive europium doped UiO-66-based ratiometric light-up biosensor for highly sensitive detection of histidinemia biomarker.
    Analytica chimica acta· 2024· PMID 38246745mais citado
  4. The self-assembly of L-histidine might be the cause of histidinemia.
    Scientific reports· 2023· PMID 37838762mais citado
  5. Spiropyran-modified upconversion nanocomposite as a fluorescent sensor for diagnosis of histidinemia.
    RSC advances· 2020· PMID 35515791mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:2157(Orphanet)
  2. OMIM OMIM:235800(OMIM)
  3. MONDO:0009345(MONDO)
  4. GARD:6661(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q725845(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Histidinemia
Compêndio · Raras BR

Histidinemia

ORPHA:2157 · MONDO:0009345
Prevalência
1-9 / 100 000
Herança
Autosomal recessive
CID-10
E70.8 · Outros distúrbios do metabolismo de aminoácidos aromáticos
CID-11
Início
Infancy, Neonatal
Prevalência
0.0 (Europe)
MedGen
UMLS
C0268642
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades